Author

T. Mukohara

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Open access Sep 2026

E7389-LF as a first-line chemotherapy for patients with metastatic/advanced HER2-negative breast cancer: results from the phase 1 dose-expansion part of study 114

There is an ongoing need for first-line (1L) chemotherapies for metastatic HER2-negative breast cancer. This study evaluated the efficacy and safety profile of the dose-expansion part 6 of Study 114 in patients receiving E7389-LF as a 1L chemotherapy for metastatic/advanced HER2-negative breast cancer. Japanese patient...

Hiroshi Ishiguro, Y. Miyoshi, H. Yasojima et al. · Breast Cancer Research · 0 citations

Open access Sep 2026

Changes and clinical impact of HER3 and ERBB3 expression in primary and recurrent ovarian cancer.

OBJECTIVE Human epidermal growth factor receptor (HER) 3, encoded by the ERBB3 gene, transduces signals most effectively when dimerized with HER2. Although HER3 protein expression has been considered a poor prognostic factor in ovarian cancer, limited data exist on changes in HER3 protein expression and ERBB3 messenger...

K. Yokosu, Riu Yamashita, Satoshi Fujii et al. · Journal of Gynecologic Oncol... · 0 citations

Open access Sep 2026

Potential of β-catenin inhibitors as a novel therapeutic strategy for PIK3CA/CTNNB1 double-mutant endometrial cancer

Endometrial cancer (EC) is one of the most prevalent gynecological malignancies. EC is characterized by limited therapeutic options and a substantial unmet medical need, particularly in advanced or metastatic stages. Although a high prevalence of concurrent PIK3CA and CTNNB1 mutations has been reported in patie...

Takehiro Nakao, R. Kamata, Hitoshi Saito et al. · Cell Death Discovery · 0 citations